Federal drug regulators are weighing a decision, expected around Aug. 25, 2026, on a treatment regimen that pushed median survival past two years in patients with an aggressive form of stomach cancer. The regimen combines two targeted drugs with chemotherapy for people whose tumors carry a specific genetic marker, and in its pivotal trial it extended survival well beyond the current standard of care. If cleared, it would offer a new first-line option for a cancer that is often diagnosed late and difficult to treat.
The Aug. 25 FDA decision
The Food and Drug Administration set a target action date of Aug. 25, 2026, for a supplemental application covering tislelizumab, sold as Tevimbra, in combination with zanidatamab, sold as Ziihera, and chemotherapy. The proposed use is first-line treatment of unresectable, locally advanced or metastatic HER2-positive gastric, gastroesophageal junction or esophageal adenocarcinoma. A report on upcoming regulatory decisions noted that the application was under review through the agency’s Real-Time Oncology Review program, a pathway designed to speed evaluation of promising cancer therapies by letting reviewers examine data as it becomes available.
A target action date, sometimes called a PDUFA date, is the deadline the agency sets for itself to decide on an application. It is not a guarantee of approval, and the FDA can approve, reject or delay a decision. The agency’s Oncology Center of Excellence oversees such reviews and publishes information on how it evaluates cancer drugs and expedited programs.
Survival past two years in the HERIZON-GEA-01 trial
The application rests on the HERIZON-GEA-01 trial, whose results were presented at a major gastrointestinal cancer meeting in January 2026. In that study, the zanidatamab-containing regimen produced a median overall survival of 26.4 months, compared with 19.2 months for a regimen built on trastuzumab plus chemotherapy, the established HER2-targeted approach. That difference corresponded to a roughly 28% reduction in the risk of death. The regimen also improved median progression-free survival, the time before the cancer worsened, to 12.4 months versus 8.1 months.
Both drugs in the combination work in ways that differ from older HER2 therapy. Zanidatamab is a bispecific antibody engineered to bind two separate sites on the HER2 protein at once, while tislelizumab is an immune checkpoint inhibitor that helps the immune system attack tumor cells. Coverage of the priority review noted that the survival and progression benefits were observed regardless of PD-L1 status, a marker that often predicts response to immunotherapy, suggesting the benefit extended across patient subgroups.
Why HER2-positive stomach cancer is hard to treat
Stomach and gastroesophageal cancers are frequently diagnosed at an advanced stage, when the tumor has already spread and cannot be removed with surgery. The National Cancer Institute notes that outcomes depend heavily on how early the disease is found and on its molecular features. Roughly a fifth of these cancers are HER2-positive, meaning the tumor cells overproduce a protein that drives their growth. For years, the standard for that subset has been trastuzumab, an antibody targeting HER2, combined with chemotherapy.
Pushing median survival past two years in the metastatic setting would be a meaningful step for a disease in which survival has historically been measured in months. The regimen does not cure the cancer, but extending the time before progression and the overall length of survival can substantially affect patients’ quality and length of life, particularly when the added drugs are tolerable enough to combine with chemotherapy.
What approval would and would not change
If the FDA clears the combination, it would give oncologists a new first-line regimen for HER2-positive gastric, gastroesophageal junction and esophageal adenocarcinoma, positioned against the trastuzumab-based standard. Approval would also validate the strategy of pairing a dual-targeting HER2 antibody with an immune checkpoint inhibitor in this cancer, potentially influencing how similar combinations are studied elsewhere.
Several caveats apply. The survival figures come from a single pivotal trial, and real-world outcomes can differ from those in controlled studies. The regimen’s benefit must be weighed against its side effects and cost, and eligibility would be limited to patients whose tumors test HER2-positive, which requires molecular testing that is not universally available. A favorable decision would also cover a specific line of therapy and set of tumor types, not all stomach cancers.
A decision to watch in late August
The pending action illustrates how molecularly targeted treatment continues to reshape oncology, carving cancers into subgroups defined by genetic markers and matching each to increasingly specific drugs. For patients with HER2-positive gastroesophageal cancer, the question in late August is whether a regimen that outperformed the existing standard in its trial will become an approved option.
Because the target date falls only days after the trial data and regulatory timeline were publicly summarized, the outcome remained undecided as of this writing. Whatever the agency concludes, the HERIZON-GEA-01 results have already established a new survival benchmark that future treatments for this cancer will be measured against.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
